Please login to the form below

Not currently logged in
Email:
Password:

GSK appoints rare diseases research head

Birgitte Volck moves to the company from Swedish Ophan Biovitrum

GSK Sobi Birgitte VolckGlaxoSmithKline has appointed Birgitte Volck has its new head of rare diseases R&D.

She will join GSK after working her six months notice at Swedish Ophan Biovitrum (Sobi), which she joined four years ago and where she served as its chief medical officer.

Sobi's president and CEO Geoffrey McDonough said: "We thank Birgitte for her leadership and dedication which has helped to evolve Sobi's patient oriented research and development organisation into a highly skilled international team.

"Birgitte joined Sobi in 2012 and has been instrumental in advancing Sobi's late stage development projects and in bringing new treatment options to people with rare diseases."

Prior to joining Stockholm-based Sobi Volck spent five years at Amgen, where she served as executive development director, bone, neuroscience and inflammation, international R&D.

Before Amgen she held positions with Genzyme as Nordic medical director and project director and at Denmark's Pharmexa as vice president, clinical development and medical affairs.

15th January 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics